Skip to main content
. Author manuscript; available in PMC: 2021 Nov 9.
Published in final edited form as: Sci Immunol. 2021 Mar 5;6(57):eabe3218. doi: 10.1126/sciimmunol.abe3218

Fig. 3. Upregulated ChAT-eGFP expression in ILC2s after IL-33 treatment.

Fig. 3.

(A to C) Representative flow cytometry plots (A), population frequencies (B) and mean fluorescence intensities (C) of ChAT+ ILC2s in sort-purified small intestinal ILC2s in vitro cultured for 3 days in IL-2 and IL-7 with or without IL-33. (D to I) Representative flow cytometry plots (D and G), population frequencies (E and H) and numbers (F and I) of ChAT+ ILC2s in the lung (D to F) and mLNs (G to I) of PBS or IL-33-treated ChATBAC-eGFP mice, gated on total ILC2s. (J to L) Representative population frequencies of ChAT+ ILC2s in the mLNs (J), ceca (K) or lung (L) of TSLP or IL-25-treated (J), T. muris-infected (K), or Alternaria-treated (L) ChATBAC-eGFP mice, gated on total ILC2s. Data are representative of two independent experiments. n = 3 mice per group. Data are mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.